Novel prognostic score based on the preoperative total bilirubin-albumin ratio and fibrinogen-albumin ratio in ampullary adenocarcinoma

Table 1 Comparing the baseline characteristics of different score groups in ampullary adenocarcinoma

Variables	Total (n = 188)	Score-0 (n = 88)	Score-1 (n = 84)	Score-2 (n = 16)	P value
Gender, n (%)					0.166
Male	112 (59.574)	58 (65.909)	47 (55.952)	7 (43.750)
Female	76 (40.426)	30 (34.091)	37 (44.048)	9 (56.250)
Age, median (IQR)	58 (50, 64)	58 (51, 64)	59 (50, 66)	53 (45, 64)	0.449
Differentiation, n (%)					0.052
Poor	73 (38.830)	34 (38.636)	36 (42.857)	3 (18.750)
Moderate	70 (37.234)	38 (43.182)	27 (32.143)	5 (31.250)
Well	45 (23.936)	16 (18.182)	21 (25.000)	8 (50.000)
Tumor size, n (%)					0.479
≤ 2 cm	94 (50.000)	43 (48.864)	45 (53.571)	6 (37.500)
> 2 cm	94 (50.000)	45 (51.136)	39 (46.429)	10 (62.500)
AST (U/L), median (IQR)	57 (35, 112)	72 (48, 126)	50 (23, 94)	30 (20, 72)	< 0.001
ALT (U/L), median (IQR)	87 (36, 150)	105 (66, 186)	54 (29, 117)	45 (18, 70)	< 0.001
CEA (ng/mL), median (IQR)	2.75 (1.88, 3.81)	3.06 (1.85, 4.48)	2.58 (1.92, 3.78)	2.24 (1.94, 2.97)	0.193
CA199 (U/mL), median (IQR)	55.80 (18.83, 184.30)	60.84 (27.41, 162.30)	55.80 (13.57, 191.40)	35.46 (20.32, 72.94)	0.444
Perioperative transfusion, n (%)					0.226
No	96 (51.064)	45 (51.136)	46 (54.762)	5 (31.250)
Yes	92 (48.936)	43 (48.864)	38 (45.238)	11 (68.750)
T stage, n (%)					0.088
I	36 (19.149)	10 (11.364)	21 (25.000)	5 (31.250)
II	57 (30.319)	28 (31.818)	23 (27.381)	6 (37.500)
III	95 (50.532)	50 (56.818)	40 (47.619)	5 (31.250)
Examined lymph nodes, median (IQR)	11 (7, 18)	12 (8, 18)	11 (6, 19)	9 (4, 10)	0.044
Examined lymph node, n (%)					0.035
< 12	107 (56.915)	47 (53.409)	46 (54.762)	14 (87.500)
≥ 12	81 (43.085)	41 (46.591)	38 (45.238)	2 (12.500)
Lymph node metastasis, n (%)					0.402
No	140 (74.468)	63 (71.591)	63 (75.000)	14 (87.500)
Yes	48 (25.532)	25 (28.409)	21 (25.000)	2 (12.500)
TNM stage, n (%)					None
I	82 (43.617)	32 (36.364)	40 (47.619)	10 (62.500)
II	76 (40.426)	37 (42.045)	33 (39.286)	6 (37.500)
III	30 (15.957)	19 (21.591)	11 (13.095)	0 (0.000)
Vessel invasion, n (%)					None
No	141 (75.000)	57 (64.773)	68 (80.952)	16 (100.000)
Yes	47 (25.000)	31 (35.227)	16 (19.048)	0 (0.000)
Postoperative complications, n (%)					0.353
No	110 (58.511)	49 (55.682)	49 (58.333)	12 (75.000)
Yes	78 (41.489)	39 (44.318)	35 (41.667)	4 (25.000)
Adjuvant treatment, n (%)					0.235
No	134 (71.277)	59 (67.045)	61 (72.619)	14 (87.500)
Yes	54 (28.723)	29 (32.955)	23 (27.381)	2 (12.500)
Fibrinogen (g/L), median (IQR)	3.68 (3.12, 4.22)	3.71 (3.20, 4.02)	3.74 (3.15, 4.42)	3.06 (2.67, 3.96)	0.153
Albumin (g/L), median (IQR)	37.10 (31.40, 41.20)	39.00 (35.40, 41.40)	35.70 (27.60, 41.70)	4.13 (3.82, 4.47)	< 0.001
Total bilirubin (μmol/L), median (IQR)	38.70 (12.82, 173.60)	161.90 (63.10, 228.80)	15.31 (8.96, 24.58)	1.32 (0.75, 1.99)	< 0.001
FAR, median (IQR)	0.106 (0.086, 0.150)	0.095 (0.086, 0.109)	0.134 (0.084, 0.195)	0.687 (0.174, 0.764)	< 0.001
TBAR, median (IQR)	0.538 (0.205, 2.325)	0.266 (0.162, 0.580)	1.807 (0.386, 3.303)	3.694 (2.742, 5.027)	< 0.001

IQR: Interquartile range; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; TNM: Tumor-node-metastasis; FAR: Fibrinogen-albumin ratio; TBAR: Total bilirubin-albumin ratio.